Rituximab for side effects of immunotherapy in melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if rituximab can help treat moderate to severe side effects caused by immunotherapy (checkpoint inhibitors) in people with melanoma. If you have had immunotherapy for melanoma in the last 3 months and are now dealing with troublesome side effects, this study may offer a way to manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with melanoma (confirmed by biopsy).
- You received immunotherapy (like Opdivo, Keytruda, Yervoy, or similar) for melanoma within the last 3 months.
- You are experiencing side effects from immunotherapy that are grade 2 to 4 (moderate to severe, as rated by your doctor).
- You are 18 years old or older.
- You can understand and read Danish.
- If you can become pregnant, you must have a negative pregnancy test and use effective contraception during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with advanced melanoma (a serious skin cancer) feel during treatment with immunotherapy. It aims to better understand the symptoms they experience, so doctors can help manage them.
This trial tests if rituximab, a targeted immune therapy, can help people with a newly identified antibody-linked condition. You may qualify if you have positive anti-vimentin antibodies in spinal fluid and signs of active disease such as new MRI lesions or worsening symptoms.
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
This study looks at whether physical activity can help reduce side effects from immunotherapy in people with melanoma. You may join if you are starting a certain type of immunotherapy for melanoma.
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Immune-Related Adverse Events trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.